Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
Primary Purpose
Coronary Arteriosclerosis
Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
OFDI imaging
Sponsored by
About this trial
This is an interventional screening trial for Coronary Arteriosclerosis focused on measuring Coronary Artery Disease, Atherosclerosis
Eligibility Criteria
Inclusion Criteria:
- Undergoing PCTI for coronary artery disease
- Women with childbearing potential must have a negative pregnancy test within the 7 days prior to study entry
Exclusion Criteria:
- Kidney insufficiency (i.e., GFR<50ml/min)
- OR pregnancy
- OR people who have had a ST elevation heart attack will be excluded for at least 72 hours post-heart attack and until cardiac enzymes return to normal. People who have had a non-ST elevation heart attack will be excluded if they have evidence of ongoing ischemia, defined as chest pain or new electrocardiogram (ECG) changes in the 12 hours prior to study entry and/or rising creatine kinase (CK) and CK-MB serum enzymes.
- OR high-risk and complex lesions, including tortuous blood vessels and lesions with thrombosis
- OR unprotected left main coronary artery disease
- OR enrolled in another investigational clinical trial within the 6 months prior to study entry
- OR severe peripheral vascular disease
- OR active ischemia
- OR congestive heart failure
- OR prior coronary artery bypass surgery
- OR emergent procedures
- OR inability to return for study follow-up procedures
Sites / Locations
- Massachusetts General Hospital
- Lahey Clinic
- Columbia Presbyterian Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
OFDI imaging
Intravenous Ultrasound
Arm Description
OFDI catheter advanced to the distal coronary artery
Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
Outcomes
Primary Outcome Measures
Determine prevalence of vulnerable plaques
Number of subjects with vulnerable plaques
Secondary Outcome Measures
Full Information
NCT ID
NCT00540761
First Posted
September 24, 2007
Last Updated
January 12, 2023
Sponsor
Massachusetts General Hospital
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00540761
Brief Title
Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
Official Title
Natural History of Vulnerable Coronary Plaques
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
July 25, 2007 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Atherosclerosis, a condition in which fatty deposits of plaque build up along the inner walls of arteries, is a condition that may increase the risk of having a heart attack. Previous studies have shown that the presence of a specific kind of plaque, known as vulnerable plaque, is often found in people who have had a heart attack. This study will use a new imaging technique called optical frequency domain imaging (OFDI) to examine the presence of vulnerable plaques in people with coronary artery disease.
Detailed Description
Atherosclerosis is a condition in which deposits of fat, cholesterol, and other substances build up along the inner walls of arteries; these deposits are known as plaque. As plaque builds up, it increases the risk of heart attack. Previous autopsy studies have shown that vulnerable plaques, a type of atherosclerotic plaque, are commonly found in people who have had a heart attack. Until recently it has been difficult to identify vulnerable plaques in people prior to their death. Many people who have coronary artery disease and are at risk of having a heart attack undergo angioplasty, a procedure that opens a narrowed or blocked blood vessel. During angioplasty, imaging devices are often used to take pictures of the inside of blood vessels. The most commonly used imaging device, an intravenous ultrasound (IVUS) catheter, is threaded through the blood vessels and uses sound waves to take pictures. An OFDI is a new type of catheter that takes more detailed pictures of blood vessel walls and plaques. The additional detail provided by OFDI images may improve detection of vulnerable plaques, which may help physicians identify people who are at high risk of having a heart attack. This study will use standard IVUS imaging and OFDI to examine vulnerable plaques within blood vessels of the heart and to evaluate any changes that occur over time in heart blood vessels and plaque.
This study will enroll people with coronary artery disease who are undergoing angioplasty. At a baseline study visit, participants will first undergo an angiography procedure, in which x-ray pictures will be taken of the heart blood vessels. Participants will then be randomly assigned to undergo either the IVUS procedure followed by the OFDI procedure or vice versa. Repeat angiographies will occur after each imaging procedure. Next, participants will undergo angioplasty and a stent will be placed at the area of the blood vessel that is narrowed or blocked to keep the blood vessel open. Finally, participants will undergo repeat IVUS and OFDI procedures. For some participants, the study physician may perform the IVUS and OFDI procedures only after the angioplasty. Every six months and for a period of two years, participants will complete questionnaires about medication history and heart problems that may have occurred since the baseline visit.Blood collection will occur if this is done during office visit.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Arteriosclerosis
Keywords
Coronary Artery Disease, Atherosclerosis
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
OFDI imaging
Arm Type
Experimental
Arm Description
OFDI catheter advanced to the distal coronary artery
Arm Title
Intravenous Ultrasound
Arm Type
Experimental
Arm Description
Randomization to determine whether Intravenous Ultrasound will be conducted before or after OFDI imaging.
Intervention Type
Device
Intervention Name(s)
OFDI imaging
Intervention Description
Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
Primary Outcome Measure Information:
Title
Determine prevalence of vulnerable plaques
Description
Number of subjects with vulnerable plaques
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Undergoing PCTI for coronary artery disease
Women with childbearing potential must have a negative pregnancy test within the 7 days prior to study entry
Exclusion Criteria:
Kidney insufficiency (i.e., GFR<50ml/min)
OR pregnancy
OR people who have had a ST elevation heart attack will be excluded for at least 72 hours post-heart attack and until cardiac enzymes return to normal. People who have had a non-ST elevation heart attack will be excluded if they have evidence of ongoing ischemia, defined as chest pain or new electrocardiogram (ECG) changes in the 12 hours prior to study entry and/or rising creatine kinase (CK) and CK-MB serum enzymes.
OR high-risk and complex lesions, including tortuous blood vessels and lesions with thrombosis
OR unprotected left main coronary artery disease
OR enrolled in another investigational clinical trial within the 6 months prior to study entry
OR severe peripheral vascular disease
OR active ischemia
OR congestive heart failure
OR prior coronary artery bypass surgery
OR emergent procedures
OR inability to return for study follow-up procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Guillermo Tearney, MD, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Lahey Clinic
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
Columbia Presbyterian Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20407116
Citation
Waxman S, Freilich MI, Suter MJ, Shishkov M, Bilazarian S, Virmani R, Bouma BE, Tearney GJ. A case of lipid core plaque progression and rupture at the edge of a coronary stent: elucidating the mechanisms of drug-eluting stent failure. Circ Cardiovasc Interv. 2010 Apr;3(2):193-6. doi: 10.1161/CIRCINTERVENTIONS.109.917955. No abstract available.
Results Reference
derived
Learn more about this trial
Identifying Vulnerable Plaques in Blood Vessels of the Heart Using a New Imaging Technique
We'll reach out to this number within 24 hrs